Last reviewed 2026-04-19 · How we verify

EPANOLOL

Phase 2 active Small molecule

EPANOLOL is a epanolol drug. It is currently in Phase 2 development.

Epanolol works by interacting with a specific target to produce a therapeutic effect.

Epanolol is a small molecule drug in the epanolol class, but specific details about its target and mechanism of action are unknown. It is not clear if it is FDA approved or off-patent. As a result, there is limited information available about its commercial status or approved indications. Further research is needed to understand the pharmacology and clinical use of epanolol. Its bioavailability is 8%, but other pharmacokinetic parameters are unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EPANOLOL
Drug class	epanolol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact mechanism of epanolol is not well understood, but it is thought to work by binding to a specific protein or receptor in the body, which then triggers a series of chemical reactions that ultimately lead to its therapeutic effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EPANOLOL CI brief — competitive landscape report
EPANOLOL updates RSS · CI watch RSS

Frequently asked questions about EPANOLOL

What is EPANOLOL?

EPANOLOL is a epanolol drug.

How does EPANOLOL work?

Epanolol works by interacting with a specific target to produce a therapeutic effect.

What drug class is EPANOLOL in?

EPANOLOL belongs to the epanolol class. See all epanolol drugs at /class/epanolol.

What development phase is EPANOLOL in?

EPANOLOL is in Phase 2.

Drug class: All epanolol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing